Novo Nordisk’s obesity drug Wegovy (Semaglutide 2.4 mg) has outperformed Tirzepatide in reducing cardiovascular risk, according to new real-world evidence. Data from the STEER study, unveiled at the European Society of Cardiology (ESC) Congress 2025 in Madrid, showed that Wegovy users with obesity and cardiovascular disease were significantly less likely to suffer heart attacks, strokes or death compared to those taking Tirzepatide.

Compared with Tirzepatide, Wegovy showed 57 percent greater risk reduction for heart attack, stroke and cardiovascular-related death or death from any cause, in people with overweight or obesity and CVD, who did not have any gaps in their treatment lasting more than 30 days. There were 15 (0.1 percent) of these cardiovascular events recorded with Wegovy, and 39 events (0.4 percent) were recorded with Tirzepatide. The average follow-up duration was 3.8 months for the Wegovy group and 4.3 months for the Tirzepatide group.

In all treated people, regardless of any gaps in their treatment, Wegovy showed a significant 29 percent risk reduction for heart attack, stroke and death from any cause compared with Tirzepatide (over an average follow-up of 8.3 months for Wegovy and 8.6 months for Tirzepatide.

“Our landmark trial, SELECT, showed that Wegovy is associated with a significant 20 percent risk reduction of cardiovascular events, backed up with even greater risk reductions in the real-world studies SCORE and STEER. The results are clear – STEER demonstrates that Wegovy cuts the risk of heart attack, stroke or death by 57 per cent compared to Tirzepatide. This data confirms that Semaglutide stands apart as the only available GLP-1-based medication with proven cardiovascular benefits for people living with obesity and cardiovascular disease, without diabetes,” said Ludovic Helfgott, Executive Vice President and Head –Product and Portfolio Strategy, Novo Nordisk.